Sanofi ends Phase 1 trial of STAT6 degrader partnered with Nurix
Sanofi told Nurix it is stopping development of SAR448272 and shutting down the program, cutting off related milestone and royalty payments to Nurix.
Nurix Therapeutics disclosed in an 8-K dated November 3, 2026 that Sanofi S.A. notified the company of its decision to stop the Phase 1 first-in-human trial of SAR448272, an oral STAT6 degrader, and to end the SAR448272 program.1
The decision has financial consequences for Nurix. The company said it no longer expects to receive any future development, regulatory, or commercial milestone payments, or royalties, that it had been eligible for under the Sanofi collaboration tied to the SAR448272 program.1
Nurix noted that the rest of its partnership with Sanofi is unaffected by this specific decision. According to the filing, Nurix is still eligible for milestones and royalties tied to other licensed programs under the Sanofi collaboration, if Sanofi chooses to advance any of them further into clinical candidates.1
In its forward-looking statements section, Nurix flagged uncertainty around the rest of the collaboration. The company said there is a risk that Sanofi will decide against moving forward with the other licensed programs in the collaboration, as well as broader risk that any of its collaborators could slow or stop development of partnered programs1, along with other risks detailed in its Form 10-Q for the fiscal quarter ended August 31, 2026, and other SEC filings.
The 8-K was signed by Christine Ring, Nurix's Chief Legal Officer, on November 3, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.